VCYT - VERACYTE, INC.

33.85
-0.830   -2.452%

Share volume: 964,111
Last Updated: 03-06-2026
Healthcare/Services – Health: -0.05%

PREVIOUS CLOSE
CHG
CHG%
$34.68
-0.83
-0.02%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
20%
Profitability 0%
Dept financing 4%
Liquidity 75%
Performance 30%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-6.00%
1 Month
-7.84%
3 Months
-23.69%
6 Months
4.28%
1 Year
5.72%
2 Year
48.79%
Key data
Stock price
$33.85
P/E Ratio 
50.16
DAY RANGE
$33.11 - $34.28
EPS 
$0.84
52 WEEK RANGE
$22.61 - $50.71
52 WEEK CHANGE
$11.42
MARKET CAP 
3.328 B
YIELD 
N/A
SHARES OUTSTANDING 
79.458 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
08-05-2025
BETA 
1.13
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,090,734
AVERAGE 30 VOLUME 
$943,974
Company detail
CEO: Marc A. Stapley
Region: US
Website: veracyte.com
Employees: 790
IPO year: 2013
Issue type: Common Stock
Market: XNAS
Industry: Healthcare/Services – Health
Sector: Services

Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas. It is also developing Percepta Genome Atlas to help inform lung cancer treatment decisions.

Recent news